A share price of Vertex Pharmaceuticals, Inc [VRTX] is currently trading at $471.76, up 2.09%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VRTX shares have gain 3.63% over the last week, with a monthly amount glided 11.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] stock has seen the most recent analyst activity on February 12, 2025, when Canaccord Genuity upgraded its rating to a Hold and also boosted its price target to $424 from $408. Previously, Canaccord Genuity upgraded its rating to Hold on February 11, 2025. On January 30, 2025, downgrade downgraded it’s rating to Equal Weight but maintained its price target of $460 on the stock. H.C. Wainwright reiterated its Buy rating and decreased its price target to $535 on December 20, 2024. Oppenheimer downgraded its rating to a Perform. Jefferies upgraded its rating to Buy for this stock on December 09, 2024, and upped its price target to $550. In a note dated November 14, 2024, Citigroup initiated an Buy rating and provided a target price of $575 on this stock.
Vertex Pharmaceuticals, Inc experienced fluctuations in its stock price throughout the past year between $377.85 and $519.88. Currently, Wall Street analysts expect the stock to reach $494.56 within the next 12 months. Vertex Pharmaceuticals, Inc [NASDAQ: VRTX] shares were valued at $471.76 at the most recent close of the market. An investor can expect a potential return of 4.83% based on the average VRTX price forecast.
Analyzing the VRTX fundamentals
Trailing Twelve Months sales for Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] were 10.98B which represents 14.56% growth. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.02%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is -0.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.02, Equity is -0.03 and Total Capital is -0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 465.07 points at the first support level, and at 458.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 475.28, and for the 2nd resistance point, it is at 478.81.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] is 2.69. In addition, the Quick Ratio stands at 2.35 and the Cash Ratio stands at 1.28. Considering the valuation of this stock, the price to sales ratio is 11.03, the price to book ratio is 7.39.
Transactions by insiders
Recent insider trading involved Tatsis Ourania, EVP, Chief Reg. & Quality Off., that happened on Feb 18 ’25 when 244.0 shares were sold. EVP and Chief Legal Officer, Biller Jonathan completed a deal on Feb 18 ’25 to sell 1657.0 shares. Meanwhile, SVP & Chief Accounting Officer Ambrose Kristen sold 671.0 shares on Feb 18 ’25.
